**Abstract**

Flavonoids are polyphenolic secondary metabolites classified as anthocyanins, chalcones, flavones, flavonols, flavanones, and isoflavonoids. The antibacterial, antifungal, anti-inflammatory, and anticancer properties of flavonoids are attractive for biomedical purposes. The anticancer potential of many flavonoids is wellknown. However, the effect of some of them against human health concerns, such as lung cancer (LC), remains elusive. LC is the leading cause of cancer mortality worldwide. LC is classified into small-cell lung cancer (SCLC; 15%) and non-small cell lung cancer (NSCLC; 85%). Through PubMed, Google Scholar, and SciFinder databases, we addressed the distribution, chemical features, and therapeutic properties of flavonoids. Furthermore, we focused on the chemical characteristics, sources, biosynthesis, pharmacokinetics, anticancer, and anti-NSCLC activities of four selected flavonoids: luteolin, naringenin, kaempferol, and baicalein. The four selected flavonoids interfere with metastatic processes, promote apoptotic events, and diminish the proliferation of NSCLC cells, although further studies are required to extend our knowledge about the anti-NSCLC properties, efficacy, safety, and toxicity of the selected flavonoids. In the foreseeable future, the four selected flavonoids (alone or in combination) may be prospective candidates for drug design against NSCLC.

**Keywords:** lung cancer, non-small cell lung cancer, natural products, secondary metabolites, flavonoids
